Psychopharmacology and Psychiatry Updates podcast

KarXT: A New Era in Antipsychotics?

0:00
12:32
Rewind 15 seconds
Fast Forward 15 seconds

In this episode, we explore KarXT, a newly FDA-approved antipsychotic with a groundbreaking cholinergic mechanism, through the lens of a single powerful metric: the Number Needed to Treat. Could an NNT of 5 change how you approach treatment-resistant schizophrenia?

Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.

More episodes from "Psychopharmacology and Psychiatry Updates"